The Animal Health Industry a track record of innovation

1
The Animal Health Industrya track record of
innovation

• Paul van Aarle DVM
• Director Institutional Sales
• Intervet International b.v.

2
Subjects

• The industry and its environment
• Innovation and success
• Enabling factors

3
Our mission

• We want to be
• an animal health industry which is economically
  viable and innovation driven, contributing to a
  healthy and safe food supply as well as a high
  level of animal health and welfare
• Please visit www.ifah.be

4
Consolidation of the Animal Health Industry

(1990 2004)
73
49
1990 Top 10 companies held almost 50 of the
total 2004 Top 10 companies held almost 73
of the total market
5
Central EU registrations
Average per year 3.5 innovative
registrations 11 variations / product
6
Growth and innovation

• Global Animal Health market Real growth 1995
  2005 2.9 per year
• Forecasted real growth 1.9 for coming years
  (Wood Mackenzie 2006)
• Overall characteristics mature stable market
  with fewer players and fewer innovations
• RD increased budgets, product maintenance
  grows at the expense of innovation
• Results more consolidation and less new
  products, more expensive projects ? risk aversion

7
Subjects

• The industry and its environment
• Innovation and success
• Enabling factors

8
Innovation track record

• 2 new chemical entities per year (1996-2005)
• 1.5 new biological entities per year (1996-2005)
• First recombinant DNA vaccine in 1984
• First deletion marker-vaccine in 1989
• First monoclonal product in 1990
• First vector vaccine in 2002

9
Some success-stories

• FMD eradication with the help of vaccination
• Marker-vaccines e.g. Aujeszkys disease, IBR,
  Classical Swine Fever, FMD
• Single shot new antibiotics
• Pet health and welfare effective and safe
  control of parasitic diseases of pets
• Food safety Salmonella (example)
• Vector vaccines
• Pox and Marek vectors
• Live Newcastle Disease / Avian Influenza vaccine
  for mass application
• Targeted replacement of treatment by vaccination
  (example)

10
Effect of vaccination against FMD
11
Incidence human Salmonellosis in England and
Wales
Salenvac-vaccination implemented in Lion Code
Incidence human salmonellosis
All
S.E.
PT4
S.tm
Other
Year
Source Advisory Committee on the Microbiological
Safety of Food (ACMSF), UK, 2001
Trademark registered in 1 or more countries
12
Norwegian salmon production, consumption of pure
antibiotics and effect of vaccines
Vibriosis vaccine
60
350
300
50
Furunculosis vaccine
250
40
Oil-based vaccines
200
Tons of Antibiotics (black bars)
30
1'000 Tons of Salmon (red line)
Combination vaccines
150
20
100
10
50
0
0
1987
1989
1991
1993
1995
1997
1981
1983
1985
Source Norwegian Ministry of Fisheries and
Coastal Affairs, 2005
13
Subjects

• The industry and its environment
• Innovation and success
• Enabling factors

14
Enabling factors

• Basic research
• increase academic focus
• increase EU funding
• streamline national and EU research
• embrace new technology (acceptance)
• strategic partnerships
• Applied research
• review and rationalise existing regulations
• simplify variation procedures
• speak and act as 1 Europe